Freenome Reports Positive Results for SimpleScreen CRC Test

Health
Health
Business Update
Business Update

Show Chart?

Load external content from TradingView!

*You can change or withdraw your consent at any time in the footer under Cookies.

Freenome Reports Successful Clinical Validation for Updated SimpleScreen CRC Blood Test

Brisbane, CA - Freenome Holdings, Inc. has announced favorable results from its pivotal clinical validation study for its updated SimpleScreen CRC blood-based colorectal cancer screening test. The study successfully met all primary and secondary endpoints, demonstrating significant performance improvements, particularly in the detection of advanced precancerous lesions (APLs).

Key Highlights:

... Read on — Members only

About Freenome Holdings, Inc.

Freenome is an early cancer detection company developing blood-based tests to detect cancer when it is most treatable. The company recognizes that no single technology can identify every cancer due to the disease’s inherent heterogeneity. Freenome’s approach combines a multiomics platform that analyzes multiple signals in the blood with artificial intelligence and machine learning to tune into cancer’s subtlest clues, even at the earliest stages of the disease.

View Company Details

SPAC IPO Calendar
SPAC IPO Events
Scroll to Top